Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4544681
Max Phase: Preclinical
Molecular Formula: C53H68ClN9O12S
Molecular Weight: 1090.70
Molecule Type: Unknown
Associated Items:
ID: ALA4544681
Max Phase: Preclinical
Molecular Formula: C53H68ClN9O12S
Molecular Weight: 1090.70
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCN(CC(=O)NCCOCCOCCOCCOCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1
Standard InChI: InChI=1S/C53H68ClN9O12S/c1-33(2)75-44-30-38(35(5)29-42(44)59-53-57-31-39(54)49(61-53)58-40-10-6-7-12-45(40)76(69,70)34(3)4)36-15-19-62(20-16-36)32-47(65)56-18-22-72-24-26-74-28-27-73-25-23-71-21-17-55-41-11-8-9-37-48(41)52(68)63(51(37)67)43-13-14-46(64)60-50(43)66/h6-12,29-31,33-34,36,43,55H,13-28,32H2,1-5H3,(H,56,65)(H,60,64,66)(H2,57,58,59,61)
Standard InChI Key: QTBMHRVZWBBKIB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1090.70 | Molecular Weight (Monoisotopic): 1089.4397 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kargbo RB.. (2019) PROTACs and Targeted Protein Degradation for Treating ALK-Mediated Cancers., 10 (8): [PMID:31413792] [10.1021/acsmedchemlett.9b00296] |
Source(1):